Cargando…

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial

BACKGROUND: Beta-thalassemia major patients typically require chronic transfusion and iron-chelating agents to reduce serum iron overload. Osveral(®) is an available Iranian brand name of deferasirox used by majority of thalassemic patients. The aim of this study was to compare the efficacy of Osver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rafati, Mohammadreza, Karami, Hossein, Lashtoo-Aghaee, Bita, Lashtoo-Aghaee, Bahareh, Dabirian, Mojdeh, Avan, Razieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Babol University of Medical Sciences 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797811/ https://www.ncbi.nlm.nih.gov/pubmed/35178209 http://dx.doi.org/10.22088/cjim.13.1.61

Ejemplares similares

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Sewage and sewage-contaminated environments are the most prominent sources to isolate phages against Pseudomonas aeruginosa
por: Aghaee, Bahareh Lashtoo, et al.
Publicado: (2021)

Evaluation of soluble human leukocyte antigen-G in peripheral blood of pregnant women with gestational diabetes mellitus
por: Shobeiri, Saeide-sadat, et al.
Publicado: (2016)

Improving the Inhibitory Effect of Phages against Pseudomonas aeruginosa Isolated from a Burn Patient Using a Combination of Phages and Antibiotics
por: Aghaee, Bahareh Lashtoo, et al.
Publicado: (2021)

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2011)

Renal Function in Patients with Thalassemia Major Receiving Exjade(®) Dispersible Tablets and a New Film-coated Tablet Formulation of Deferasirox (Nanojade(®))
por: Falahati, Vahid, et al.
Publicado: (2022)

Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®)
por: Vini, Dimitra, et al.
Publicado: (2011)

Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study
por: Eshghi, P., et al.
Publicado: (2011)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)
por: Di Tucci, Anna Angela, et al.
Publicado: (2007)

Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox
por: Ghazanfari, Azam, et al.
Publicado: (2019)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Jadenu(®) Substituting Exjade(®) in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles
por: Yassin, Mohamed A, et al.
Publicado: (2018)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
por: Wu, Dijiong, et al.
Publicado: (2018)

Deferasirox in Indian children with thalassemia major: 3 years experience
por: Dhamija, Mayank, et al.
Publicado: (2013)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
por: Taher, Ali T., et al.
Publicado: (2013)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
por: Ricchi, Paolo, et al.
Publicado: (2015)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
por: Elli, Elena Maria, et al.
Publicado: (2014)

Juvenile hemochromatosis: HAMP mutation and severe iron overload treated with phlebotomies and deferasirox
por: Lescano, Manuel A, et al.
Publicado: (2017)

Efficacy and Safety of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching Hospital
por: Thakor, Dhaval R, et al.
Publicado: (2017)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
por: Porter, John, et al.
Publicado: (2012)

The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan
por: Chang, Hsiu-Hao, et al.
Publicado: (2015)

Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy
por: Soliman, Ashraf, et al.
Publicado: (2014)

Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha
por: Panigrahi, Mousumee, et al.
Publicado: (2020)

Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow
por: Shen, J.C., et al.
Publicado: (2017)

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
por: Vichinsky, Elliott, et al.
Publicado: (2007)

Trade names that have become generic names in anaesthesia
por: Abraham, AA
Publicado: (2012)

Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients
por: Ghazaiean, Mobin, et al.
Publicado: (2023)

Trading upon a Name
por: Lippe, Ad.
Publicado: (1887)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major
por: Ejaz, Muzamil Shabana, et al.
Publicado: (2015)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2f7tacopp2agn6vcdbsv0h8ik6